IL22 and colitis: Notably, treatment with an anti-IL-22 antibody has been demonstrated to suppress myofibroblast proliferation and subsequent fibrotic symptoms, a common complication of CD, in a trinitrobenzene sulfonic acid (TNBS)-induced colitis model [59].